Arabic Arabic English English French French German German

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer

BeiGene, Ltd., a global biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental Biologics License Application for anti-PD-1 antibody tislelizumab in combination with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer. Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member

Next Post

LUNGevity Foundation and Partner Hamoui Family Foundation Issue 2022 Request for Applications for RET-Positive Clinical Lung Cancer Research

Related Posts